Relias Media - Continuing Medical Education Publishing

The trusted source for

healthcare information and

CONTINUING EDUCATION.

  • Sign In
  • Sign Out
  • MyAHC
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    Home » Blogs » HICprevent » Vaccine Efficacy Questionable Against Predominant Flu Virus

    HICprevent
    HICprevent RSS FeedRSS

    HIC Prevent

    This award-winning blog supplements the articles in Hospital Infection Control & Prevention.

    Vaccine Efficacy Questionable Against Predominant Flu Virus

    Innoculate
    December 15, 2017
    No Comments
    Reprints
    Facebook Twitter Linkedin Share Share

     

    By Gary Evans, Medical Writer 

    Influenza activity is higher than normal thus far this season, and most cases are being caused by a virus that may be ill matched to the vaccine, the Centers for Disease Control and Prevention reports.

    “Influenza A (H3N2) viruses were most commonly reported during week 48 – the week ending December 2, 2017 – and have been the predominant virus so far this season,” the CDC reported. "Of the 347 influenza A viruses that were subtyped, 314 (90.5%) were H3N2 viruses and 33 (9.5%) were (H1N1) pdm09 viruses.

    Based on the flu season in Australia, which used the same vaccine now recommended in the United States, immunization may only afford scant protection against H3N2, says Anthony Fauci, MD, director of the NIH National Institute of Allergy and Infectious Diseases (NIAID).

    “Since we are using the same vaccine that was used in Australia and it looks like the virus now is similar to the virus that was circulating in Australia, it is likely – not definite, but likely – that we will have a rough season with influenza,” he says. “Whether [the vaccine] is going to be 10% effective – or 15%, 20% or 5% – it is very difficult to put an exact number on it. But the one thing that we do know is that the vaccine that was grown in eggs is a bit of a mismatch with the circulating virus.”

    That said, flu immunization is still strongly recommended to protect against other circulating strains and gain as much immunity as possible to the H3N2 strain. As the old adage notes, even a partially effective flu shot can keep you out of the hospital or the morgue.

    For more on this story, see the January 2018 issue of Hospital Infection Control & Prevention. 

    Post a comment to this article

    Report Abusive Comment

    Shop Now: Search Products

    • Subscription Publications
    • Books & Study Guides
    • Webinars
    • Group & Site
      Licenses
    • State CME/CE
      Requirements

    Webinars And Events

    View All Events
    • Home
      • Home
      • Newsletters
      • Blogs
      • Archives
      • CME/CE Map
      • Shop
    • Emergency
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Hospital
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • Clinical
      • All Products
      • Publications
      • Study Guides
      • Webinars
      • Group Sales
    • All Access
      • Subscribe Now
      • My Subscription
    • My Account
      • My Subscriptions
      • My Content
      • My Orders
      • My CME/CE
      • My Transcript
    • Help
    • Search
    • About Us
    • Sign In
    • Register
    Relias Media - Continuing Medical Education Publishing

    The trusted source for

    healthcare information and

    CONTINUING EDUCATION.

    Customer Service

    customerservice@reliasmedia.com

    U.S. and Canada: 1-800-688-2421

    International +1-404-262-5476

    Accounts Receivable

    1-800-370-9210
    ReliasMedia_AR@reliasmedia.com

    Mailing Address

    • 1010 Sync St., Suite 100
      Morrisville, NC 27560-5468
      USA

    © 2021 Relias. All rights reserved.

    Do Not Sell My Personal Information  Privacy Policy  Terms of Use  Contact Us  Reprints  Group Sales

    For DSR inquiries or complaints, please reach out to Wes Vaux, Data Privacy Officer, DPO@relias.com

    Design, CMS, Hosting & Web Development :: ePublishing